Company Projected Revenue: Omega Therapeutics Inc (OMGA)

Public company logo of Omega Therapeutics (OMGA)

Omega Therapeutics relies on reserves due to a lack of profitability and the costs of testing. The organization's planned commercial revenue shows slowing momentum, with the metric currently standing at 0.01. Growth is constrained by strict FDA oversight and patent barriers, although its status as an epigenetics pioneer and confidence within the biotech sector create a foundation for future breakthroughs in cancer therapy.

OMGA - Omega Therapeutics Projected Sales Volume over the range 07/04/2022 - 03/08/2025

Summary analytical data breakdowns for Omega Therapeutics (OMGA)

- company stock exchange capitalization indicators:
Comprehensive company analysis:Omega Therapeutics OMGA
Brand item of Omega Therapeutics Corp

This indicator assesses long-term revenue potential through the lens of market expectations. An analysis of Omega Therapeutics (OMGA) target sales volumes on GURU.Markets allows for the tracking of the issuer's commercial potential revaluation. The metric is calculated as the aggregate of projected cash flows from future product sales. However, for Omega Therapeutics (OMGA), these figures remain hypothetical. The absence of commercial drugs and the early research stage render the company a pure capital consumer.

Key competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|Company Projected Revenue metagenomi.co|Projected Sales Volume Precision BioSciences Inc.|Projected Sales Volume GBIO|Boundless Bio, Inc. - Company Revenue Forecast|Projected Sales Volume XCUR (Exicure, Inc.)|Company Future Sales Imunon, Inc. (IMNN)|PHIO - Company Projected Revenue|Company Future Revenue MBIO (mustangbio.com)|RNAZ: Projected Sales Volume|Company Revenue Forecast BNGO|APDN (Applied DNA Corp) - Projected Sales Volume|BLUE: Company Future Revenue|Company Projected Revenue ImmunoPrecise (IPA)|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume